Sharma MR - Search Results

1

Prolonged Pharmacokinetic Interaction Between Capecitabine and a CYP2C9 Substrate, Celecoxib.

Ramírez J, House LK, Karrison TG, Janisch LA, Turcich M, Salgia R, Ratain MJ, Sharma MR. Ramírez J, et al. Among authors: sharma mr. J Clin Pharmacol. 2019 Dec;59(12):1632-1640. doi: 10.1002/jcph.1476. Epub 2019 Jul 5. J Clin Pharmacol. 2019. PMID: 31274208 Clinical Trial.

2

Capecitabine and Celecoxib as a Promising Therapy for Thymic Neoplasms.

Wood K, Byron E, Janisch L, Salgia R, Sharma MR. Wood K, et al. Among authors: sharma mr. Am J Clin Oncol. 2018 Oct;41(10):963-966. doi: 10.1097/COC.0000000000000400. Am J Clin Oncol. 2018. PMID: 28654574 Free PMC article.

3

Models of excellence: improving oncology drug development.

Sharma MR, Maitland ML, Ratain MJ. Sharma MR, et al. Clin Pharmacol Ther. 2012 Nov;92(5):548-50. doi: 10.1038/clpt.2012.99. Clin Pharmacol Ther. 2012. PMID: 23085878 Free PMC article.

4

Evaluation of food effect on pharmacokinetics of vismodegib in advanced solid tumor patients.

Sharma MR, Karrison TG, Kell B, Wu K, Turcich M, Geary D, Kang SP, Takebe N, Graham RA, Maitland ML, Schilsky RL, Ratain MJ, Cohen EE. Sharma MR, et al. Clin Cancer Res. 2013 Jun 1;19(11):3059-67. doi: 10.1158/1078-0432.CCR-12-3829. Epub 2013 Apr 3. Clin Cancer Res. 2013. PMID: 23553850 Free PMC article. Clinical Trial.

5

Taking a Measured Approach to Toxicity Data in Phase I Oncology Clinical Trials.

Sharma MR, Ratain MJ. Sharma MR, et al. Clin Cancer Res. 2016 Feb 1;22(3):527-9. doi: 10.1158/1078-0432.CCR-15-2005. Epub 2015 Oct 14. Clin Cancer Res. 2016. PMID: 26467385 Free PMC article.

6

A pharmacodynamic study of sirolimus and metformin in patients with advanced solid tumors.

Sehdev A, Karrison T, Zha Y, Janisch L, Turcich M, Cohen EEW, Maitland M, Polite BN, Gajewski TF, Salgia R, Pinto N, Bissonnette MB, Fleming GF, Ratain MJ, Sharma MR. Sehdev A, et al. Among authors: sharma mr. Cancer Chemother Pharmacol. 2018 Aug;82(2):309-317. doi: 10.1007/s00280-018-3619-3. Epub 2018 Jun 9. Cancer Chemother Pharmacol. 2018. PMID: 29948021 Free PMC article. Clinical Trial.

7

Estimation of renal cell carcinoma treatment effects from disease progression modeling.

Maitland ML, Wu K, Sharma MR, Jin Y, Kang SP, Stadler WM, Karrison TG, Ratain MJ, Bies RR. Maitland ML, et al. Among authors: sharma mr. Clin Pharmacol Ther. 2013 Apr;93(4):345-51. doi: 10.1038/clpt.2012.263. Epub 2012 Dec 27. Clin Pharmacol Ther. 2013. PMID: 23443753 Free PMC article.

8

Why RECIST works and why it should stay--reply to counterpoint.

Sharma MR, Maitland ML, Ratain MJ. Sharma MR, et al. Cancer Res. 2012 Oct 15;72(20):5158. doi: 10.1158/0008-5472.CAN-12-1988. Epub 2012 Sep 4. Cancer Res. 2012. PMID: 22952220 No abstract available.

9

RECIST: no longer the sharpest tool in the oncology clinical trials toolbox---point.

Sharma MR, Maitland ML, Ratain MJ. Sharma MR, et al. Cancer Res. 2012 Oct 15;72(20):5145-9; discussion 5150. doi: 10.1158/0008-5472.CAN-12-0058. Epub 2012 Sep 4. Cancer Res. 2012. PMID: 22952219

10

A phase I study of sirolimus and bevacizumab in patients with advanced malignancies.

Cohen EE, Sharma MR, Janisch L, Llobrera M, House L, Wu K, Ramirez J, Fleming GF, Stadler WM, Ratain MJ. Cohen EE, et al. Among authors: sharma mr. Eur J Cancer. 2011 Jul;47(10):1484-9. doi: 10.1016/j.ejca.2011.02.017. Epub 2011 Mar 23. Eur J Cancer. 2011. PMID: 21439817 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

145 results

Search Page